Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes
- PMID: 17494017
- PMCID: PMC1867899
- DOI: 10.1136/bmj.39202.399942.AD
Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes
Abstract
Women in western countries are more likely to die from heart disease than from cancer. Scott M Grundy argues that the risks make preventive treatment essential, but Malcolm Kendrick believes the evidence of benefit is not strong enough
Conflict of interest statement
Comment in
-
Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.BMJ. 2007 May 12;334(7601):983. doi: 10.1136/bmj.39202.397488.AD. BMJ. 2007. PMID: 17494018 Free PMC article.
References
-
- National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Final report. Circulation 2002;106:3143-421. - PubMed
-
- Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004;110:227-39. - PubMed
-
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9. - PubMed
-
- Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000;102:1893-900. - PubMed
-
- Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources